Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Gains from Sales and Divestitures (2022 - 2025)

Oramed Pharmaceuticals' Gains from Sales and Divestitures history spans 3 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, changed N/A, while the annual FY2025 figure was $1.9 million, N/A changed from the prior year.
  • Gains from Sales and Divestitures reached $1.9 million in Q4 2025 per ORMP's latest filing, up from $521625.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.9 million in Q4 2025 to a low of $218000.0 in Q4 2022.
  • Average Gains from Sales and Divestitures over 3 years is $873243.0, with a median of $521625.0 recorded in 2023.
  • The largest YoY upside for Gains from Sales and Divestitures was 139.28% in 2023 against a maximum downside of 139.28% in 2023.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $218000.0 in 2022, then skyrocketed by 139.28% to $521625.0 in 2023, then soared by 260.43% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Gains from Sales and Divestitures are $1.9 million (Q4 2025), $521625.0 (Q4 2023), and $218000.0 (Q4 2022).